MAP4K1 and central nervous system cancer: We found that patients with comparatively higher levels of MAP4K1 mRNA had a lower rate of overall survival than patients with low levels of MAP4K1 mRNA, suggesting that MAP4K1 up-regulation signifies a poorer prognosis for patients with gliomas.